Patricia Stewart

May 28, 2024 | theoncologypharmacist.com | William King |Patricia Stewart |Charlie Dawson |Wayne Kuznar

Get TOP in Your Inbox! Stay up to date with the latest oncology pharmacy news and insights by subscribing to our eNewsletter.

May 28, 2024 | theoncologypharmacist.com | Patricia Stewart |Charlie Dawson |William King |Phoebe Starr

Get TOP in Your Inbox! Stay up to date with the latest oncology pharmacy news and insights by subscribing to our eNewsletter.

Mar 18, 2024 | theoncologypharmacist.com | William King |Patricia Stewart |Charlie Dawson

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years.1 In recent years, the diagnosis of CRC has been shifting to a younger age and a more advanced stage.1,2 In fact, 1 in 5 new cases of CRC occurs in people aged <50, and more individuals are diagnosed at an advanced stage now than in the mid-1990s before widespread screening.1 Consensus is lacking as to why colorectal cancer is rising in...

Sep 10, 2023 | theoncologypharmacist.com | Patricia Stewart |William King

"Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC" was originally published by CCA News. Surufatinib, a small-molecule inhibitor targeting VEGFR1, VEGFR2, VEGFR3, FGFR1, and CSF-1R, has exhibited satisfactory clinical effectiveness and favorable safety and tolerability profiles when utilized as monotherapy in the treatment of patients with biliary tract cancer (BTC) in the second-line setting.

Jun 20, 2023 | theoncologypharmacist.com | Anne Rowe |William King |Patricia Stewart |Charlie Dawson

Get TOP in Your Inbox! Stay up to date with the latest oncology pharmacy news and insights by subscribing to our eNewsletter.